Pharmacogenetic of the Antihypertensive Response to the Angiotensin II Blockers in Monotherapy or Associated to Hydrochlorothiazide.

Trial Profile

Pharmacogenetic of the Antihypertensive Response to the Angiotensin II Blockers in Monotherapy or Associated to Hydrochlorothiazide.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2009

At a glance

  • Drugs Hydrochlorothiazide; Losartan
  • Indications Essential hypertension
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 24 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Sep 2008 Planned end date changed from 1 Apr 2009 to 1 Jun 2009 as reported by CT.gov
    • 25 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top